KHENERGY: completion of recruitment and first-in-patient dosing

Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical trial with KH176 in MELAS/MIDD and mixed mitochondrial syndromes NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical company...

EFRO Grant to support the KHENERGYC study

THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial disease NIJMEGEN, the Netherlands – Khondrion, the clinical-stage pharmaceutical company focusing on small molecule therapeutics for...

KH176 Phase 2 clinical trial

Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes NIJMEGEN, The Netherlands – Khondrion, the clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial...

Khondrion partner in REMIX EU research project

Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU research initiative REMIX aims to combine the skills of European research groups to provide strategic training of the next generation of scientists...